{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Angiogenesis > SunitinibCAS：557795-19-4
Molecular Formula：C22H27FN4O2
Molecular Weight：398.47
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：Light yellow to yellow Solid
Qty：
Size：
| CAS | 557795-19-4 |
| Name | Sunitinib |
| Molecular Formula | C22H27FN4O2 |
| Molecular Weight | 398.47 |
| Solubility | Soluble in DMSO ≥25mg/mL |
| Purity | HPLC≥98% |
| Appearance | Light yellow to yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD08273555 |
| SMILES | O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C |
| Target Point | VEGFR;PDGFRβ |
| Passage | Angiogenesis;Protein Tyrosine Kinase/RTK |
| Background | Sunitinib is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR2 and PDGFRβ. |
| Biological Activity | Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2]. |
| Data Literature Source | [1]. Sun L，et al. Discovery of 5-[5-fluoro-2-oxo-1，2- dihydroindol-(3Z)-ylidenemethyl]-2，4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide，a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003 Mar 27;46(7):1116-9. [2]. Ali MM，et al. Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J. 2011 Mar 2;30(5):894-905. [3]. O'Farrell AM，et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. [4]. Mendel DB，et al. In vivo antitumor activity of SU11248，a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can |
| Unit | Piece |
| Specification | 50mg 10mM*1mL in DMSO 100mg 200mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
